microscopy of csf & body fluids · 2019. 5. 29. · microscopy of csf & body fluids may 13,...

86
Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials & PharmaDx ARUP Laboratories Tracy I. George, MD

Upload: others

Post on 02-Nov-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Microscopy of CSF & Body

Fluids

May 13, 2019

Professor of Pathology

University of Utah Health

Executive Director, Clinical Trials & PharmaDx

ARUP Laboratories

Tracy I. George, MD

Page 2: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Objectives

• Distinguish benign from malignancy cytology on

CSF and body fluids

• Recommend appropriate further evaluation when

necessary

2

Page 3: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Agenda

Item 1 Cytopreparatory Methods

Item 2 Cerebrospinal Fluid

Item 3 Pleural Fluid

Item 4 Peritoneal Fluid

Item 5 Pericardial fluid

3

Page 4: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Cytopreparatory Methods

o Centrifugation w/ preparation from sediment

o Cytocentrifugation

o ThinPrep™

o Membrane filtration

o Cell block preparation

o Immunohistochemistry, in situ hybridization, molecular studies

Page 5: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Agenda

Item 1 Cytopreparatory Methods

Item 2 Cerebrospinal fluid

Item 3 Pleural Fluid

Item 4 Peritoneal Fluid

Item 5 Pericardial fluid

5

Page 6: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Tubes

• Tube 1: Chemistry & immunologic studies

• Tube 2: Microbiologic studies

• Tube 3: Cell count & cytologic examination

In a traumatic tap, after centrifugation the supernatant fluid will clear

+/- clot, no xanthochromia

Page 7: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Cerebrospinal Fluid

Cell type Adult Neonate

WBC <5/mL <30/mL

RBC Few Variable

Lymphs 40-80% 5-35%

Monos 15-45% 50-90%

PMNs 0-6% 0-8%

Correction for bloody tap is usually 1-2 wbc/1,000 rbc

Page 8: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Cns lymphocytes

Monocytes

Lymphocytes

Page 9: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Benign vs. Malignant

• Round to oval nucleus

with a regular nuclear

contour; prominent

and distinct nuclear

membrane

• Irregular nuclear shape;

indistinct nuclear

membrane, may have

“blebs” at periphery

Nuclear contour/nuclear membrane

N:C ratio

• Low to moderate • High

Page 10: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Benign or Malignant?

Page 11: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Choroid Plexus Cells

Page 12: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Benign vs. Malignant

• Fine or uncondensed

nuclear chromatin

with uniform, smooth

texture

• Uneven nuclear texture;

prominent

parachromatin spaces

may occur

Nuclear texture

Nucleoli

• Small to medium-

sized, if any are

present

• Large and angulated

nucleoli

Page 13: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Diagnosis?

Page 14: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Ependymal Cells

Page 15: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Benign or malignant?

Page 16: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

CNS ganglion cells

Page 17: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Diagnosis?

Page 18: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Bone marrow contamination

Page 19: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Bacterial Meningitis

Page 20: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Diagnosis?

Page 21: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Cryptococcus neoformans

Page 22: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Benign vs. Malignant

• Heterogeneous with

different morphologic

forms

• Round to bean-

shaped nuclei with

regular contours

• Clear Golgi zone often

present

• Homogeneous infiltrate

of malignant cells

• Nuclei may have

uneven contours

• Golgi region often

absent in lymphoma

cells

Lymphoid cells

Page 23: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Diagnosis?

Page 24: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Viral meningitis

Page 25: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Benign vs. Malignant

• Nuclear chromatin

varies from

condensed to blastic

(in the immunoblast)

• Several small nucleoli

may be present

• Blastic nuclear

chromatin in all cells

• Nucleoli may be large

Lymphoid cells

Page 26: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Diagnosis?

Page 27: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Acute Leukemia

Page 28: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Benign vs. Malignant

• Benign cells have thin

spaces (“windows”)

• Outer border of cell

cluster is

discontinuous

• 3-D clusters with

morula-like appearance

• Outer border of cell

cluster is continuous

and smooth, and may

be darkly stained due to

cell overlap

Cell clusters

Page 29: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Benign or malignant?

Page 30: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Medulloblastoma

Page 31: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

CS-WG

Large Cell Lymphoma

TP-Pap CS-WG

1000x oil

TP-Pap

Page 32: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

TP-Pap CS-WG

1000x oil

Acute Lymphoblastic Leukemia

Page 33: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Agenda

Item 1 Cytopreparatory Methods

Item 2 Cerebrospinal Fluid

Item 3 Pericardial Fluid

Item 4 Pleural Fluid

Item 5 Peritoneal Fluid

33

Page 34: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Transudates vs. Exudates

• Fluid protein/serum protein ≤ 0.5 >0.5

• Fluid LDH/serum LDH ≤ 0.6 >0.6

• LDH ≤ 200 >200

clear cloudy

pale yellow turbid

purulent

bloody

benign malignant

infection

Page 35: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Pericardial Fluid

• Constitute ~ 1% serous effusions

• Most are exudates

– malignancy; infection; trauma; MI; leaking aneurysm; RA; SLE; anti-coag therapy

• Transudates

Congestive heart failure; RA; sarcoidosis; hypothyroidism

• Lymphocytosis:

Adult: TB

Child: Viral

Rarely lymphoma

Page 36: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Sources of Malignancy in Pericardial Fluid

Malignant cytology: 27%

1. Breast: 33%

2. Colon: 20%

3. Lung: 20%

4. Lymphoma/leukemia: 7%

5. Misc/Unknown: 20%

Zipf RE. The role of cytology in the evaluation of pericardial fluids. Chest 1972;62:593-596

Page 37: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Etiology of Pleural Effusions

• Malignancy 25% - 45%

• CHF 12%

• Infection 22%

(TB, Bacterial, Viral, Fungal, etc)

• Indeterminant 10%

• Pulmonary embolism/Infarct 3%

• Cirrhosis 2%

• Collagen Dz 2%

Hausheer F. Dx & Treatment of malignant pleural effusions. Semin Oncol. 1985;12(1):54-75

Page 38: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Pleural effusions

Transudate

• CHF

• Cirrhosis

• Hypoproteinemia

• Nephrotic syndrome

• Atelectasis

• Myxedema

• Peritoneal dialysis

• PE

• Meig’s syndrome

• Obstructive uropathy

Exudate

• Malignancy

• Infection

• Trauma

• Pulmonary infarction

• PE

• Autoimmune dz

• Pancreatitis

• Ruptured esophagus

Page 39: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Peritoneal Effusions

Transudate

• CHF

• Cirrhosis

• Hypoproteinemia

• Nephrotic syndrome

• Hepatic vein occlusion

• Hepatic metastasis

Exudate

• Malignancy

• Infection

• Trauma

• Pancreatitis

• Bile peritonitis

Page 40: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Malignant Ascitic Fluid

Male

Misc 38 - 46.4%

GI tract 23.8 - 42.8%

Unknown 14.2 - 16.6%

Lung 4.7 - 9.5%

FemaleGenital Tract 50.6 - 61%Misc. 13.2 - 15.5%Breast 10.3 - 17.6%GI Tract 9.0 - 9.7%Unknown 3.8 - 8.3%Lung 0 - 1.7%

Page 41: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Macrophage & Mesothelial Cells

Page 42: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Macrophages

Page 43: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials
Page 44: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Multinucleated Giant Cells

Page 45: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Pigment Laden Macrophages

Page 46: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Mesothelium

Page 47: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Mesothelial Cells

Page 48: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Mesothelial Cells

Page 49: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Mesothelial Variability

Page 50: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Signet Ring Mesothelials

Page 51: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Mesothelial Windows

Page 52: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Mesothelial Hyperplasia

Page 53: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

“Embracing” Mesothelials

Page 54: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Mesothelial Clumps

Page 55: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Mesothelial Mitoses

Page 56: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Mesothelial erythrophagocytosis

Pap

stain

Page 57: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Diagnosis?

Page 58: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Malignant Mesothelioma

Page 59: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Immunohistochemistry

Mesothelioma

Calretinin

CK 5/6

Two toned

cytoplasm

Adenocarcinoma

CEA

CD15

Ber EP-4

B72.3

Homogeneously

distributed stain

Page 60: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Calretinin immunostain

Page 61: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Electron Microscopy

AdenocarcinomaMesothelioma

Page 62: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Benign vs. Malignant

• Unusual cells may be

present, but there is a

heterogeneity of

morphologic features,

with a gradation of

normal to reactive

cells

• Atypical, distinct

population of bizarre

cells are seen that do

not resemble any

known benign variant

Unusual homogenous population

Page 63: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Lymphocytes

Page 64: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Diagnosis?

Page 65: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Large cell lymphoma

Page 66: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Diagnosis?

Page 67: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Burkitt lymphoma

Page 68: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Diagnosis?

Page 69: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Primary Effusion Lymphoma

Page 70: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Features of Adenocarcinoma

Cell groups

Solid cell balls

Papillary forms

Free-floating acini

Columnar cell fronds

Single-cell rows

Individual cells

Signet-ring forms

Intracytoplasmic

lumena

Clear cell change

Intracytoplasmic dot

Multinucleated giant

cells

Page 71: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Breast carcinoma

Page 72: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Diagnosis?

Page 73: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Breast Carcinoma

Page 74: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Ovarian Carcinoma

Page 75: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Papillary Serous Carcinoma

Page 76: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Diagnosis?

Page 77: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Lung Adenocarcinoma

Page 78: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Diagnosis?

Page 79: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Breast Carcinoma

Page 80: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Benign vs. Malignant

• Tiny, poorly defined

vacuoles can be seen

in any degenerating

cell

• Phagocytic vacuoles

• Mesothelial cells

• Vacuoles in malignant cells usually represent synthesized material (e.g. mucin)

• Adenocarcinoma often has large vacuoles with a smooth, well-defined border and a clear interior. Vacuoles may coalesce in adjacent cells

Cytoplasmic vacuoles

Page 81: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Pancreatic Adenocarcinoma

Page 82: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Breast Carcinoma

Page 83: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Gastric Adenocarcinoma

Page 84: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

•Benign vs. Malignant Criteria•Nuclear Contour

•Nuclear texture

•Nucleoli

•N:C ratio

•Mitoses

•Nuclear molding

•Cytoplasmic vacuoles & granules

•Signet-ring cells

•Cell clusters

•Unusual population

•Reactive vs malignant lymphoid cells

Conclusions

Page 85: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

Recommended Reading

• CAP Color Atlas of Body Fluids

• Kjeldsberg Body Fluids

85

Page 86: Microscopy of CSF & Body Fluids · 2019. 5. 29. · Microscopy of CSF & Body Fluids May 13, 2019 Professor of Pathology University of Utah Health Executive Director, Clinical Trials

© ARUP Laboratories2014